MBX Biosciences Common Stock (MBX) Financials

Balance sheets

30 Sept 202401 June 202401 Dec 202330 Sept 2023

Total Assets

$282.4 M(+349.1%)$62.9 M(-25.3%)$84.2 M-

Current Assets

$281.2 M(+378.2%)$58.8 M(-29.6%)$83.5 M-

Non Current Assets

$1.2 M(-69.9%)$4.1 M(+470.8%)$715.0 K-

Total Liabilities

$11.0 M(-93.1%)$160.8 M(+2.6%)$156.6 M-

Current Liabilities

$10.9 M(+33.2%)$8.2 M(+108.8%)$3.9 M-

Long Term Liabilities

$112.0 K(-99.9%)$152.6 M(-0.1%)$152.7 M-

Shareholders Equity

$271.4 M(+377.2%)-$97.9 M(-35.1%)-$72.5 M-

Book Value

$271.4 M(+377.2%)-$97.9 M(-35.1%)-$72.5 M-

Working Capital

$270.3 M(+434.1%)$50.6 M(-36.4%)$79.5 M-

Cash And Cash Equivalents

$132.9 M(+962.7%)$12.5 M(-59.0%)$30.5 M-

Accounts Payable

$5.0 M(+55.3%)$3.2 M(+131.6%)$1.4 M-

Accounts Receivable

----

Short Term Debt

-$162.0 K(+5.9%)$153.0 K-

Long Term Debt

$44.0 K(-49.4%)$87.0 K(-49.1%)$171.0 K-

Total Debt

$210.0 K(-15.7%)$249.0 K(-23.1%)$324.0 K-

Debt To Equity

0.0(0%)0.0(0%)0.0-

Current Ratio

25.8(+259.1%)7.2(-66.3%)21.3-

Quick Ratio

----

Inventory

----

Retained Earnings

-$121.9 M(-17.5%)-$103.8 M(-37.3%)-$75.6 M-

PB Ratio

2.9---

Income statements

30 Sept 202401 June 202401 Dec 202330 Sept 2023

EPS

-$2.8---$0.3

TTM EPS

-$2.8---$0.3

Revenue

$0.0--$0.0

TTM Revenue

$0.0--$0.0

Total Expenses

$19.6 M--$10.9 M

Operating Expenses

$19.6 M--$10.9 M

Cost Of Goods Sold

----

TTM Cost Of Goods Sold

----

Gross Profit

----

TTM Gross Profit

----

Gross Margin

----

Operating Profit

-$19.6 M---$10.9 M

TTM Operating Profit

-$19.6 M---$10.9 M

Operating Margin

----

Net Income

-$18.1 M---$10.2 M

TTM Net Income

-$18.1 M---$10.2 M

Net Margin

----

EBIT

-$19.6 M---$10.9 M

TTM EBIT

-$19.6 M---$10.9 M

EBITDA

-$19.5 M---$10.9 M

TTM EBITDA

-$19.5 M---$10.9 M

Selling, General & Administrative Expenses

$2.9 M--$1.9 M

TTM SG&A

$2.9 M--$1.9 M

Depreciation And Amortization

$75.0 K--$40.0 K

TTM D&A

$75.0 K--$40.0 K

Interest Expense

----

TTM Interest Expense

----

Income Tax

----

TTM Income Tax

----

PE Ratio

----

PS Ratio

----

Cashflow statements

30 Sept 202401 June 202401 Dec 202330 Sept 2023

Cash From Operations

-$14.7 M---$7.7 M

TTM CFO

-$14.7 M---$7.7 M

Cash From Investing

-$100.8 M---$18.6 M

TTM CFI

-$100.8 M---$18.6 M

Cash From Financing

$235.8 M--$68.5 M

TTM CFF

$235.8 M--$68.5 M

Free Cash Flow

-$14.7 M---$7.7 M

TTM FCF

-$14.7 M---$7.7 M

CAPEX

$57.0 K--$22.0 K

TTM CAPEX

$57.0 K--$22.0 K

Dividends Paid

----

TTM Dividends Paid

----

TTM Dividend Per Share

----

TTM Dividend Yield

----

Payout Ratio

----